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Abstract 
Carcinoma-associated mesenchymal stem cells (CA-MSCs) are critical stromal progenitor cells 
within the tumor microenvironment. We previously demonstrated that CA-MSCs differentially 
express BMP family members, promote tumor cell growth, increase cancer ‘stemness’ and 
chemotherapy resistance. Here we use RNA sequencing of normal omental MSCs and ovarian 
CA-MSCs to demonstrate global changes in CA-MSC gene expression. Using these expression 
profiles, we create a unique predictive algorithm to classify CA-MSCs. Our classifier accurately 
distinguishes normal omental, ovary and bone marrow MSCs from ovarian cancer CA-MSCs. 
Suggesting broad applicability, the model correctly classifies pancreatic and endometrial cancer 
CA-MSCs and distinguishes cancer associated fibroblasts (CAFs) from CA-MSCs.   
Using this classifier, we definitively demonstrate ovarian CA-MSCs arise from tumor mediated 
reprograming of local tissue MSCs. While cancer cells alone cannot induce a CA-MSC 
phenotype, the in vivo ovarian tumor microenvironment (TME) can reprogram omental or ovary 
MSCs to protumorigenic CA-MSCs (classifier score of >0.96). In vitro studies suggest that both 
tumor secreted factors and hypoxia are critical to induce the CA-MSC phenotype. Interestingly, 
while the breast cancer TME can reprogram BM MSCs into CA-MSCs, the ovarian TME cannot, 
demonstrating for the first time that tumor mediated CA-MSC conversion is tissue and cancer 
type dependent. Together these findings (1) provide a critical tool to define CA-MSCs and (2) 
highlight cancer cell influence on distinct normal tissues providing powerful insights into the 
mechanisms underlying cancer specific metastatic niche formation. 
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Introduction: 
 
High grade serous ovarian cancer cells (HGSOC) have a striking predilection for the intra-
peritoneal microenvironment with >70% of women presenting with intra-peritoneal metastasis 
[1].  The ovarian tumor microenvironment (TME) is not a passive backdrop but an active “organ” 
significantly altering cancer growth, survival and spread [2-4].  One critical component of the 
ovarian TME is the mesenchymal stem cell (MSC).  
MSCs reside in nearly every tissue in the body including the bone marrow, omentum and ovary, 
playing critical roles in wound healing and tissue repair [5, 6]. Carcinoma associated MSCs (CA-
MSC) are distinct from normal tissue MSCs with a unique expression profile and protumorigenic 
functions [2, 7]. CA-MSCs fulfill all the criteria for MSCs posed by the International Society for 
Cellular Therapy (ISCT): 1) plastic adherence 2) CD105, 90, 73 positivity and CD45, CD34, 
CD14, CD19, HLA-DR negativity and 3) capacity to differentiate into at least two mesenchymal-
derived cell types [8].  CA-MSCs do not have malignant potential and do not harbor tumor-
associated mutational changes such as p53 mutations (found in > 90% of all high grade serous 
ovarian tumors), thus CA-MSCs are not derived directly from tumor cells [2, 9]. As true stromal 
progenitor cells, CA-MSCs differentiate into important stromal components such as cancer 
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associated fibroblasts (CAFs) and adipocytes and may play a critical role in influencing the 
formation and function of the entire TME.  
 
CA-MSCs, compared to normal tissue MSCs, have a distinct expression profile characterized by 
high expression of Transforming Growth Factor Beta (TGF b) super family members which 
mediates their pro-tumorigenic functions including tumor growth promotion, enrichment of 
cancer stem-like cells (CSCs) and induction of chemotherapy resistance [2, 7].Thus understanding 
and targeting CA-MSCs has the potential to significantly impact ovarian cancer progression.  
Indeed, we recently described a tumor derived hedgehog (Hh) and CA-MSC derived Bone 
Morphogenetic Protein 4 (BMP4) signaling loop which, when interrupted, led to drastic tumor 
cell chemo-sensitization and regression of established cisplatin-resistant tumors [7]. 
 
CA-MSCs clearly influence the ovarian TME, however a fundamental question remains 
unanswered: what is the origin of CA-MSCs? As MSCs are highly migratory, CA-MSCs could 
be a unique population of normal MSCs recruited to the TME or could be resident cells 
induced into a protumorigenic phenotype. Identifying the origin of CA-MSCs is critical to 
targeting these pivotal stromal stem cells thus potentially disrupting the formation of the TME at 
an early stage when therapies may be most effective. 
 
Previously we reported that cancer cell secreted factors influence the expression profile of normal 
tissue MSCs [2]. We thus hypothesized that the protumorigenic CA-MSC phenotype may be 
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induced via “cancer stimulation”. To date, only select expression changes and specific signaling 
pathways have been described in MSC:tumor cell interactions. We performed RNA sequencing of 
normal MSCs and CA-MSCs and demonstrate global expression changes in CA-MSCs. We then 
used RNASeq data to develop a 6 gene CA-MSC classifier that accurately differentiates normal 
MSCs from ovarian CA-MSCs. Using this classifier, we demonstrate that normal ovarian and 
normal omental derived MSCs (OV MSCs, OM MSCs) can be induced by ovarian cancer to 
become CA-MSCs. Interestingly, the capacity to become a CA-MSC is tissue source and cancer 
type dependent as MSCs from bone marrow (BM MSCs) fail to acquire ovarian cancer promoting 
properties; however, with breast cancer stimulation, BM MSCs develop a CA-MSC phenotype 
strongly promoting breast cancer growth. Importantly, the CA-MSC classifier accurately predicts 
CA-MSC protumorigenic function including induction of tumor cell chemotherapy resistance, 
enhancement of CSCs and promotion of in vivo tumor growth. A combination of tumor secreted 
factors and other influences in the TME such as hypoxia appear to drive the CA-MSC 
phenotype.  
 
Results: 
 
Creation of an ovarian CA-MSC classifier.  We previously described a unique CA-MSC 
expression profile based on an 84-gene qRT-PCR microarray expression platform [2]. To 
comprehensively define the CA-MSC expression profile, we performed RNA sequencing on CA-
MSCs derived from (i) surgical resection of omental metastatic deposits of ovarian cancer (largely 
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high grade serous ovarian cancer) and (ii) normal omental derived MSCs (MSCs derived from 
omental tissue of women undergoing benign gynecologic surgery). K-means clustering and 
principal components regression demonstrated clear differences in the expression patterns of CA-
MSCs vs OM MSCs. Figure 1 shows the unsupervised hierarchical clustering of CA-MSC vs OM 
MSCs RNAseq data (Fig1A), principle component analysis of RNAseq data (Fig1B) and 
correlation plotting of gene enrichment scores of the top 25 differentially expressed genes from 
RNAseq analysis (green dots= positive correlations, red dots= negative correlations) (Fig1C). 
Consistent with our previous findings [2, 7], bone morphogenetic protein 2 (BMP2),  platelet-
derived growth factor receptor beta (PDGFRb), leukemia inhibitor factor (LIF) and T-box 5 
(TBX5) were significantly differentially expressed in CA-MSCs vs OM MSCs in both the 
RNAseq data (Fig1C) and independent qRT-PCR validation (Fig1D).  
RNA sequencing data was used to determine differential gene expression enrichment via the 
Sergushichev fast algorithm in CA-MSCs compared to OM MSCs. At the <0.05 adjusted p-value 
level, 27 genes were identified which discriminated between CA-MSCs and OM MSCs. 
Individual RT-PCR was performed on an additional 10 independent patient CA-MSCs and 8 
independent patient OM MSCs for each gene in the gene enrichment set (GES) to validate the 
RNAseq data. Two genes, CLND1 and EVPL, failed independent validation and were excluded 
resulting in a final 25-gene GES (Fig1C,D). The CA-MSC and OM MSC independently validated 
expression data (from the 10 independent patient CA-MSCs and 8 independent patient OM MSCs 
above), represented as the delta CT value of the mRNA expression compared to GAPDH, was 
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divided into a testing and training group. Samples were randomly divided using random number (0 
or 1) generation. Each group contained 5 CA-MSCs and 4 OM MSCs. Cross-validated constrained 
(LASSO) logistic regression modeling was applied. This method created a parsimonious model 
seeking to minimize misclassification error that predicts the probability of being a CA-MSC vs 
MSC (supFig1). The sum of regression coefficients*gene PCR expression is logistically 
transformed yielding a score between 0 and 1 of how likely the sample is a “CA-MSC.” Scores 
closest to 1 have the highest probability of being a CA-MSC and scores closest to 0 have the 
lowest probability of being a CA-MSC (or conversely, the most likely to be a normal MSC). 
Scores close to 0.5 are the least reliably interpreted due to the shape of the logistic curve and 
potential for small noise in the model translating to large change in score. The final model 
incorporated expression data from 6 genes: Annexin A8-like protein 2 (ANXA8L2), Collagen 
Type XV Alpha 1 Chain (COL15A1), Cytokine Receptor Like Factor 1 (CRLF1), GATA Binding 
Protein 4 (GATA4), Iroquois Homeobox 2 (IRX2), and Transforming Growth Factor Beta 2 
(TGFb2). A 5-gene vs 6-gene LASSO model without and with TGFb had equal misclassification 
error. The TGFb super family of proteins are functionally important in MSC biology and BMP 2 
and 4 are particularly important in tumor cell:CA-MSC interactions, thus we choose to leave this 
gene incorporated given equivalency in model performance. We henceforth refer to this model as 
the CA-MSC classifier. 
We tested the robustness of the classifier in distinguishing independent OM MSC and CA-MSC 
samples. The classifier accurately identified five new independent patient OM MSC samples as 
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“not a CA-MSC” with an average score of 0.04 and eight new independent patient CA-MSC 
samples as “CA-MSCs” with an average classifier score >0.99. With an average score of >0.99 
(n=3 patients) CA-MSCs derived from primary ovary tumors (rather than metastatic deposits) 
were also accurately classified as “CA-MSCs”. We further tested the classifier using normal 
MSCs from ovary and bone marrow. Bone marrow MSCs and ovary MSCs (n=3 each), with 
classifier scores of 0.16 and 0.18 respectively, were accurately classified as “not CA-MSCs”. With 
an inherent threshold value of 0.5, the CA-MSC classifier achieved 100% accuracy. Moreover, 
while the model was generated with a 0.5 threshold, the extremes (closest to 1 or 0) carry the most 
precision and are therefore the most reliable. The greatest variability exists surrounding the 0.5 
threshold therefor classifier scores around this number are the least reliable. To provide easier 
determination of what is reliably predicted as a CA-MSC vs normal MSC, we choose to set a 
boundary at 0.96 which is 2 standard deviations below the average CA-MSC score (average=0.99, 
standard deviation=0.015) as reliably a CA-MSC. Conversely, for normal MSCs (omentum, 
ovary, BM), the score 2 standard deviations above the average was 0.3 (average=0.11, standard 
deviation=0.09) and this was used as an upper boundary to reliably classify a normal MSC.  
We also characterized CA-MSCs from endometrial cancer (n=2 patients) and pancreatic cancer 
(n=3 patients) which were classified as “CA-MSCs” with scores of 0.96 and 0.99 respectively. 
Confirming MSCs are distinct from cancer associated fibroblasts (CAFs), ovarian and omental 
tumor tissue derived CAFs (n=2, one from omental tissue, one from ovarian tissue) yielded a 
classifier score of 0.56 which has a low probability of reflecting either a normal MSC or a CA-
MSCs profile (Fig2C). 
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Ovarian cancer cells partially induce OM and OV MSCs to assume a CA-MSC expression profile. 
To determine if cancer cells reprogram normal MSCs into CA-MSCs, we first performed in vitro 
direct and indirect co-culture experiments using normal MSCs and ovarian cancer cells. Normal 
BM MSCs, OM MSCs, or OV MSCs from three different patients per cell type were cultured with 
three ovarian cancer cell lines --SKOV3 (endometrioid), CAOV3 and PEO1 (high grade serous). 
Co-cultured MSCs were isolated and mRNA expression applied to the CA-MSC classifier.  
Previously validated differentially expressed mRNAs were also assessed (supFig2) [2]. While some 
genes showed altered expression (Fig 3 A-F), indirect co-culture of MSCs and tumor cells did not 
induce a CA-MSC expression profile in any of the MSC populations with classifier scores ranging 
from 0.12- 0.22 (SEM<0.09).   
We next determined if direct co-culture, allowing both secreted and cell-contact dependent 
interactions, could induce the formation of a CA-MSC. mTomato (mT) labeled BM MSCs, OM 
MSC or OV MSCs were co-cultured with ovarian cancer cells, FACS isolated and mRNA 
expression applied to the CA-MSC classifier. While more genes approximated expression observed 
in CA-MSCs, cancer cell stimulation via direct co-culture demonstrate limited induction of a CA-
MSC phenotype with a classifier scores of 0.17 (SEM=0.03) for BM MSC, and 0.55 (SEM=0.12) 
for OV MSC. Direct cancer stimulation of OM MSCs (D-CS OM MSC) most closely approximated 
a CA-MSC, with a classifier score of 0.87 (SEM=0.13). Several critical components of the 
signature were missing including changes in ANXA8L2 and TGF-b (Fig3, Fig5C).  
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Hypoxia enhances the induction of a CA-MSC. We considered what other factors in the TME may 
influence the induction of a CA-MSC. One hallmark of the TME [10, 11] which impacts normal 
MSC morphology, proliferation, and differentiation is hypoxia [12]. Hypoxia is known to increase 
TGF-β signaling and GATA4 expression, genes upregulated in CA-MSCs [13-17]. CA-MSCs 
demonstrated higher transcript and protein levels of hypoxia inducible factor alpha (HIF1α) and 
indirect cancer stimulation induced HIF1α expression in OM MSCs (Fig4B). Interestingly, OM 
MSCs and CA-MSCs grew slower and spontaneously formed spheroids under hypoxic conditions 
(1% oxygen) (Fig4A). We tested the impact of hypoxia on the induction of a CA-MSC profile in 
vitro. Indirect and direct co-cultures as described above were repeated under hypoxic (1% oxygen) 
conditions. MSCs were isolated and mRNA expression data was applied to the CA-MSC classifier. 
Hypoxia alone did not significantly alter normal MSCs (classifier score 0.2 (SEM0.05) ). Indirect 
and direct co-culture under hypoxic conditions (IHyp-CS, DHyp-CS respectively) yielded classifier 
scores of: 0.08 for IHyp-CS BM MSC and 0.03 for DHyp-CS BM MSC, 0.63 for IHyp-CS OM MSC 
and 0.86 for DHyp-CS OM MSC, and 0.35 for IHyp-CS OV MSC and 0.95 for DHyp-CS OV MSC 
(Fig4, Fig5C). Thus, hypoxia enhanced CA-MSC induction in OV and OM MSC, but not BM 
MSC.  
 
In vivo co-culture effectively reprograms normal MSC into CA-MSC.  We next determined if in 
vivo growth of normal MSCs with ovarian cancer cells fully induces a CA-MSC expression 
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profile. mTomato labeled OM, OV and BM MSCs were grown with GFP-labeled CAOV3 or 
PEO1 tumor cells in mouse xenografts. Tumors were resected and MSCs re-isolated (via FACS 
on mT+ cells). Re-isolated MSCs were analyzed to confirm they still met MSC-defining criteria 
outlined by the ISCT [8] (CD105+,90+,73+, 44+;CD45-, 34-, 14-, 19-) and capacity to 
differentiate into adipocytes, osteocytes and chondrocytes. Less than 1% of cells expressed 
fibroblast surface protein (FSP) or fibroblast activation protein (FAP) verifying absence of 
fibroblast contamination (SupFig4). To ensure no tumor contamination or malignant 
transformation, 1x106 re-isolated MSCs were injected into mice and monitored for tumor growth 
for 6 months without tumor initiation.  
In vivo cancer stimulation (IV-CS) of OM and OV MSCs resulted in induction of a CA-MSC 
profile (Fig 5, supFig 2) with a IV-CS OM MSC classifier score of 0.98 (SEM=0.01) and IV-CS 
OV MSC classifier score of 0.97 (SEM=0.02). TGFb expression changes did not reach CA-MSC 
levels however. In contrast, BM MSCs inhibited xenograft growth when mixed with CAOV3 or 
PEO1 tumor cells and no viable BM MSCs could be re-isolated. 
 
CA-MSC classification corresponds with protumorigenic CA-MSC functions.  The distinct 
expression profile of CA-MSCs corresponds with unique protumorigenic functions: (i) CA-
MSCs increase the CSC pool as marked by increased levels of ALDH and enhanced tumor 
sphere formation [2], and CA-MSCs enhance (ii) tumor growth and (iii) chemotherapy resistance 
[7]. We therefore determined if cancer stimulated OM MSCs classified as CA-MSCs also 
developed CA-MSC-associated pro-tumorigenic functions.  We first tested the effects of cancer-
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stimulated OM MSCs on chemotherapy resistance. Cancer stimulated OM MSCs were grown 
with GFP+ PEO1 cells (BRCA1 mutant platinum-sensitive line) or GFP+ CAOV3 cells (BRCA 
wild type, intermediate platinum-sensitivity) [18, 19] and treated with cisplatin.  Cisplatin 
treatment of cancer cells grown alone, with patient derived CA-MSCs or with control OM MSCs 
(OM MSCs without cancer stimulation) served as comparators. Control OM MSCs did not 
significantly impact cancer cell cisplatin sensitivity while cancer stimulated OM MSCs enhanced 
cancer cell cisplatin resistance to a degree proportional to their CA-MSC classifier score (Fig6). 
I-CS OM MSCs (classifier score of 0.15) did not significantly enhance CAOV3 or PEO1 
chemotherapy resistance (Fig6A). However, IHyp-CS OM MSCs (classifier score of 0.63) began 
to enhance chemotherapy resistance, especially at higher concentrations of cisplatin (Fig6A). 
Similarly, D-CS OM MSCs and DHyp-CS OM MSCs (classifier scores of 0.87 and 0.86 
respectively) enhanced chemotherapy resistance (Fig6B). IV-CS OM MSCs (classifier score of 
0.98) enhanced the chemo-resistance of platinum sensitive PEO1 cells to the greatest extent, 
equivalent to patient derived CA-MSC-induced chemotherapy resistance (Fig6 C,D). DHyp-CS 
BM MSCs which did not develop a CA-MSC expression profile (classifier score of 0.03) 
likewise failed to significantly enhance chemotherapy resistance of cancer cells (Fig6D).  
Alternatively, DHyp-CS OV MSCs which acquired a near-CA-MSC expression profile (classifier 
score of 0.95) increased tumor cell chemotherapy resistance to levels equivalent to patient 
derived CA-MSCs (Fig6D). This indicates that the CA-MSC classification of cancer stimulated 
MSCs accurately corresponds with the ability to induce cancer cell chemotherapy resistance and 
supports the importance of the CA-MSC expression profile in imparting CA-MSC associated 
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chemotherapy resistance. 
We next investigated if cancer stimulated MSCs impact ovarian CSCs by testing ovarian tumor 
sphere growth.  MSCs were mixed with GFP-CAOV3 or GFP-PEO1 tumor cells in non-adherent 
conditions and tumor spheres counted. Tumor spheres grown with MSCs demonstrated mixed 
cellularity with GFP+ tumor cells growing within/surrounded by GFP- MSCs (Fig6G). We 
observed that, relative to no MSC controls and OM MSC controls, IV-CS OM MSCs 
significantly enhanced tumor sphere numbers, equivalent to patient derived CA-MSCs (Fig6E). 
To confirm these results, spheres were dissociated and the number of GFP+ tumor cells assessed 
via FACs.  IV-CS OM MSCs likewise enhanced the absolute number of viable tumor cells 
(Fig6F).  
 
Ultimately, the primary functional feature of a CA-MSC is the ability to promote tumor growth 
in vivo [2, 7]. We therefore tested if IV-CS OM MSCs increase in vivo tumor growth similar to 
patient derived CA-MSCs. IV-CS OM MSCs were mixed with CAOV3 cells to create murine 
xenografts. Patient derived CA-MSCs or control OM MSCs were mixed with CAOV3 cells as 
control xenografts. Consistent with our previous results, patient derived CA-MSC containing 
tumors grew significantly faster and larger than tumors containing control OM MSC or control 
OV MSC or tumor cells alone (Fig7). Both IV-CS OM MSC and IV-CS OV MSCs promoted 
tumor growth at a rate equal or greater than patient derived CA-MSCs (Fig7B). These findings 
were repeated using PEO1 cancer cells likewise demonstrating growth enhancement with IV-CS 
OM MSCs (supFig 3).   
14 
 
This article is protected by copyright. All rights reserved.
Collectively, our results indicate that cancer stimulated-induction of a CA-MSC expression 
profile also conveys protumorigenic functional properties including tumor cell chemotherapy 
resistance, CSC enhancement and acceleration of in vivo tumor growth. 
 
BM MSCs do not become CA-MSCs with ovarian cancer stimulation but demonstrate growth 
promoting properties after breast cancer stimulation.  Unlike OM and OV MSCs, BM MSCs fail 
to acquire a CA-MSC expression profile or tumor promoting properties with any type of ovarian 
cancer cell stimulation. In fact, BM MSCs decreased ovarian xenograft growth (Fig7B) and 
could not be re-isolated from xenografts. As ovarian cancer rarely metastasizes to the bone, we 
investigated whether triple negative breast cancer, which frequently metastasizes to the bone but 
genetically resembles ovarian cancer, could be promoted by BM MSCs. We performed in vivo 
cancer stimulation (IV-CS) of BM MSCs with MDA-MB-231 cells (triple negative breast cancer 
cell line). BM MSCs mixed with breast cancer cells readily formed tumors but initially did not 
enhance xenograft growth compared to tumor cells alone (Fig 7C). The mixed cellularity 
xenografts were harvested and BM MSCs were re-isolated, propagated and characterized as 
above. The IV-CS BM MSCs were mixed with MDA-MB-231 cells to form xenografts. While 
the CA-MSC classifier score of breast cancer IV-CS BM MSC was only 0.17, IV-CS BM MSCs 
significantly enhanced breast tumor initiation and growth. This highlights the heterogeneity 
among sources of MSCs and their potential to develop a tumor-supporting phenotype which may 
be cancer-type specific. 
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Discussion: 
Creation of a CA-MSC classifier:  Unlike previous reports which focus on select molecular 
changes in tumor-associated MSCs, here we report the global expression differences between 
normal and cancer associated MSCs. We developed a robust algorithm which condenses these 
global changes into a 6-gene classifier which accurately distinguished not only ovarian cancer, 
but also endometrial and pancreatic derived CA-MSCs from normal MSCs. The classifier also 
distinguishes CA-MSCs from CAFs potentially clarifying another problematic area in the 
scientific literature. This classifier has the potential to be critical in the study of CA-MSCs 
allowing rapid, low cost validation.   
 
CA-MSC are derived from normal MSCs exposed to the TME: Using the CA-MSC classifier we 
addressed the important question of what is the origin of CA-MSCs? Several studies have 
suggested MSCs migrate to sites of cancer from the bone marrow. However, while our studies 
cannot rule out rare MSC populations migrating to the TME, using labeled MSCs derived from 
various tissue sources stimulated with cancer cells in vivo we definitively show that local 
abdominal tissue derived MSCs can be reprogrammed to a CA-MSC. Even in an 
immunodeficient model, cancer stimulation effectively created a CA-MSC with the only 
difference vs patient derived CA-MSCs being TGFb2 expression which may indicate immune 
cells are important to drive this change. Interestingly, the MSC source is critical to the potential 
to support tumor growth as BM MSCs could only support breast cancer and not ovarian cancer 
growth. This differential capacity to become a CA-MSC is of great importance, implying that 
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MSCs may be critical to disease specific metastatic tropism. For example, ovarian cancer rarely 
metastasizes to the bone instead primarily residing within the intra-abdominal cavity and 
particularly in omental fat. Further, there is a clear tropism for ovarian cancer cells to colonize 
the ovary, especially considering most high grade serous ovarian cancers arise in the fallopian 
tube and the ovary may be the first metastatic site. In contrast, breast cancer readily metastasizes 
to bone and the ability of breast cancer cells to influence BM MSCs to promote growth may 
allow metastatic colonization of the bone niche. While clearly much more work is needed to 
fully understand this tissue and cancer type specificity, it is an intriguing area which may reveal 
critical insights into the disease specific patterns of metastasis. This tissue specificity may also 
explain the divergent reports in the literature regarding MSCs supporting or inhibiting cancer 
growth as results will depend on the pairing of MSC source and cancer type. Reports of BM 
MSCs supporting prostate and breast cancer growth but inhibiting ovarian cancer growth [20-22] 
are consistent with this concept. 
Understanding the origin of CA-MSCs may also have significant therapeutic implications.  
Given the migratory activity and cancer tropism of MSCs, several studies have proposed using 
MSCs as therapeutic vehicles [23-26]. Our study suggests the source of MSCs in these studies is 
critical – BM MSCs could be effectively used in ovarian cancer but may be a poor source of 
MSCs for breast cancer studies.  
Ultimately, discovering the origin of CA-MSCs is critical to understanding and eventually 
targeting the development of the pro-tumorigenic microenvironment. Mechanistically unraveling 
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how normal MSCs become CA-MSCs will allow development of treatments to prevent or reverse 
these changes thus blocking the tumor-supporting properties of CA-MSCs. Further, as CA-MSCs 
differentiate into multiple tumor stromal elements such as CAFs and adipocytes, targeting this 
progenitor cell may significantly alter the entire stromal TME. Also, if the conversion of a normal 
MSC into a CA-MSC is in part due to cancer secreted factors under hypoxic conditions, then as 
the tumor grows (locally and/or in metastatic deposits), secreted factors may act in a paracrine 
manner to influence near-by tissue MSCs to start to become CA-MSCs akin to a field effect 
creating more fertile “soil” for cancer cell propagation. By blocking these ongoing signals, we 
may prevent further spread of cancer by halting the creation of this “fertile soil.”  Future work is 
needed to identify the critical factors which convert a normal tissue MSC into a CA-MSC. Also, 
understanding the factors which protect BM MSCs from developing into an ovarian CA-MSC will 
be critical to identifying targets to prevent and/or reverse the development of CA-MSCs.
18 
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Materials and methods 
 
Tissue harvesting, culture 
Patients samples were obtained in accordance with protocols approved by the University of 
Michigan’s IRB (HUM0009149) and University of Pittsburgh’s IRB (PRO17080326). Tissue 
was processed for RNA isolation as previously described [20].  MSCs were isolated as 
previously described [5]. Briefly, CA-MSCs were derived from surgical resection of human 
ovarian cancer involving the ovary and/or omental metastatic deposits.  Normal omental, 
normal ovary and normal bone marrow MSCs were derived from surgical samples of women 
undergoing surgery for benign indications or benign bone marrow biopsy (provided as a kind 
gift from Dr. M. Wicha). Cells were plated in supplemented MEBM, MSCs were selected for 
plastic adherence and cell surface marker expression (CD105, CD90, CD73, CD44 positive; 
CD34, CD24, CD45 negative). Adipocyte, osteocyte, and chondrocyte differentiation capacity 
was verified (following guidelines presented by the ISCT on the minimal criteria for defining 
multipotent mesenchymal stem cells [9]). MSCs were maintained in culture as previously 
described and used at passage 8 or below [5] (see supplemental methods for further details). 
Endometrial and pancreatic CA-MSCs were obtained as above and as a kind gift from Dr. D. 
Simeone. Ovarian and omental fibroblasts were obtained from cancer tumor samples plated 
for plastic adherence and grown with connective tissue growth factor (100ng/ml) and ascorbic 
acid (50ug/ml) for 2 weeks (as described by Lee at al. [27]).  Fibroblast differentiation was 
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verified by expression of FAP and FSP. Ovarian cancer cell lines SKOV3, CAOV-3 and 
PEO1 were obtained from ATCC. All cell lines were tested and verified negative for 
mycoplasma (last test 12/2017). Cancer cell lines were verified by ATCC. 
 
In vitro indirect/direct co-culture, normoxic and hypoxic 
Normal MSCs were grown in co-culture (indirect, direct ± hypoxia) with GFP+ SKOV3 or 
CAOV3 or PEO1 cells. For indirect co-culture, 24mm polystyrene 0.4um transwell inserts 
with 5x104 MSCs on bottom, 5x104 tumor cells on top were used. For direct co-culture, 2x105 
MSCs and 1x105 tumor cells were mixed in a T75cm dish. MSCs grown alone at equivalent 
cell numbers served as control. Co-cultures were performed for 5 days. Cells were grown at 
21% O2 for normoxic experiments and 1% O2 for hypoxic experiments (Hypoxygen H35 
Workstation, HypOxygen). Cells were sorted for mT+, GFP- MSCs after direct co-culture 
with >99% purity with double sort as needed. For all experiments, each tumor cell line was 
used in a separate MSC co-culture. RNA expression changes and resulting classifier score was 
calculated separately for each experiment and values were averaged with SEM reported for 
each co-culture condition. 
 
In vivo MSC and tumor cell co-growth 
mT-labeled MSCs + GFP-labeled CAOV3 or PEO1 cells in a 1:1 ratio (0.5x106 cells each) 
were injected into the bilateral axilla of NSG mice. NSG (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ) 
mice were used for all experiments (female, age >6 weeks). mT-labeled BM MSCs + GFP-
20 
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labeled MDA-MB-231 breast cancer cells were also injected. Upon reaching 300-500mm3 
(modified ellipsoid formula (L*W2)/2) tumors were excised/processed into single cell 
suspensions and FAC sorted to isolate mT+/GFP- MSCs. MSCs were characterized for 
expression markers and differentiation capacity as above. IV-CS OM MSCs or IV-CS OV 
MSCs were mixed with CAOV3 or PEO1 cells in a 1:1 ratio (0.5x106 cells each) and 
injected into the bilateral axilla of NSG mice. Similarly, breast cancer IV-CS BM MSCs 
were mixed with MD-MBA-231 cells and injected as above. Control MSCs and patient 
derived CA-MSCs were grown with CAOV3, PEO1 or MDA-MB-231 cells as comparators. 
Five mice with bilateral tumor per group (n=10 tumors/group).  
 
In vitro chemotherapy resistance assays 
GFP+ CAOV3 or PEO1 cells were grown ± MSCs (1:1 ratio, 20,000 total cells/24-well 
dish). I-CS, D-CS, IHyp-CS, DHyp-CS or IV-CS BM MSCs, OM MSCs and OV MSCs were 
compared to control MSCs and CA-MSCs. Tumor cells alone (20,000 cells/well) served as 
control. Cisplatin treatment lasted 24-48 hours. Viable GFP-tumor cells were analyzed via 
FACS using propidium iodide.  
 
Tumor sphere assay 
GFP+ CAOV3 or PEO1 cells were grown ± IV-CS OM MSCs (1:1 ratio, 2,000 cells total) in 
48-well non-adherent dishes in serum-free supplemented MEBM. Control MSCs or CA-MSCs 
21 
 
This article is protected by copyright. All rights reserved.
were comparators. After 7 days, GFP+ spheres were counted using fluorescent microscopy 
(Olympus BX41). Spheres were dissociated with trypsin and mechanical dispersion and FACs 
analyzed to quantify GFP+ tumor cells.  
 
RNA sequencing and data processing 
RNA was extracted from 4 OM-MSC samples and 10 CA-MSC samples per the TRIzol 
reagent manufacturer’s extraction protocol (Invitrogen). 2ug of total RNA/sample was used for 
library preparation using the TruSeq RNA Sample Preparation v2 kit (Illumina) per the 
manufacturer’s instructions using the Low Throughput protocol. Libraries were sequenced as 
paired-end 100bp on a HiSeq2000 instrument (Illumina) at the Peter MacCallum Cancer 
Centre. Each barcode-separated lane of sequencing data was aligned to the human reference 
genome and transcriptome (GRCh37) using Bowtie 2 version 2.2.3 [28] & TopHat2 v2.0.13 
[29]. Between 64,000,000 and 113,000,000 paired reads were aligned to the transcriptome 
(supplemental methods). Estimation of gene abundance was carried out using HTSeq [30] 
which were log normalized prior to downstream analysis using the R-package Limma [31]. 
Specifically, differentially expressed genes between the OM-MSC and CA-MSC were 
identified, using the parameters of a log fold change (logFC) greater than + / - 2 and a p-value 
< 0.05. The RNAseq data has been deposited to NCBI’s Gene Expression Omnibus (GEO) and 
are accessible through GEO Series accession number GSE118624 
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE118624).  
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 CAMSC Classifier Creation 
Gene expression heatmaps for CA-MSC and OM-MSC were created and compared using the 
“heatmap” package. To statistically evaluate the degree of data variability, principal 
components analysis (PCA) was run on the top-50 univariate p-value genes using the “PCA” 
and “fviz_pca” functions in R, with an ellipse alpha = 0.95 for graphical visualization. The 
signal to discriminate between the CA-MSC and OM-MSC groups was confirmed by 
hierarchical clustering analysis to optimize the Ward distance over k=2 groups using 
packages “FactoMineR” and “factoextra”. To further reduce the data, gene set enrichment 
analysis (GSEA) was performed using the Sergushichev algorithm and corresponding “fgsea” 
package [32]. We provided the “CA-MSC” or “OM-MSC” class and RNAseq data for each 
of the 14 individuals. Enrichment values were created over 10,000 permutations, and an 
adjusted p-value of 0.05 revealed 27 differentially enriched genes. These 27 differentially 
enriched genes identified from RNAseq were verified via independent qRT-PCR on 10 
additional independent CA-MSC and 8 independent OM-MSC samples (2 of the 27 genes, 
CLND1 and EVPL, failed independent validation and were excluded yielding a final 25-gene 
set). Using the qRT-PCR data, we used cross-validated L1-norm constrained logistic 
regression [33] (CV-LASSO) to select a predictive subset of genes to discriminate between 
the CA-MSC and non-CA-MSC groups. Using the “glmnet” package, we minimized the 
cross-validation misclassification error to select the largest optimum L1-norm constraint 
value lambda and extracted the non-zero classifier model coefficients from the full PCR data. 
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Experimental predictions were generated by fitting validation experiment PCR data to this 
CV-LASSO generated model and comparing predicted and true cancer cell exposures. The 
threshold for assignment from the logistic regression was 0.5. All programming was 
performed in R 3.1.0 [34].   
 
Statistics 
All in vitro experiments were repeated independently at least three times with triplicate 
samples per experiment unless otherwise stated. Statistical significance was evaluated using a 
2-sided student’s T-test. For all experiments, α=0.05. For animal studies, n=10 per group 
based on final tumor volume of control animals of ~1000mm3 with an expected standard 
deviation of 30%. 
Non-linear regression analysis of tumor growth over time was performed for each group and 
curves compared to determine statistical significance. In all figures, error bars represent 
standard error of the mean of composite values from independent experiments. 
Study approval 
Animal studies were performed with approval of the University Committee on Use and Care of 
Animals of the University of Michigan. Patients samples were obtained in accordance with a 
protocol approved by the University of Michigan’s IRB (HUM0009149) and University of 
Pittsburgh’s IRB (PRO17080326). Written informed consent was received from participants 
prior to inclusion in the studies.  Recombinant DNA work was performed in accordance with 
the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules 
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 Quantitative real-time PCR and Immunoblotting are detailed in supplementary methods. 
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